The Biosimilar Advantage: Market Pipeline Examination

The biosimilar pipeline analysis market comprises of biologic drugs that are approved through an abbreviated regulatory pathway for drugs that have already been approved, also known as reference products (originator biologics).Biosimilars offer a cost-effective alternative to originator biologics for treatments of various chronic diseases. The market is currently dominated by drugs in oncology and autoimmune disease segments with a wide number of pipeline molecules in chronic disorders like diabetes and cardiovascular disease. With patents of blockbuster biologics set to expire in coming years, biosimilars are expected to significantly reduce healthcare costs without compromising on efficacy and safety.